Prostate cancer heterogeneity: Discovering novel molecular targets for therapy

Chiara Ciccarese, Francesco Massari, Roberto Iacovelli, Michelangelo Fiorentino, Rodolfo Montironi, Vincenzo Di Nunno, Francesca Giunchi, Matteo Brunelli, Giampaolo Tortora

Risultato della ricerca: Contributo in rivistaArticolo in rivista

44 Citazioni (Scopus)


Prostate cancer (PCa) shows a broad spectrum of biological and clinical behavior, which represents the epiphenomenon of an extreme genetic heterogeneity. Recent genomic profiling studies have deeply improved the knowledge of the genomic landscape of localized and metastatic PCa. The AR and PI3K/Akt/mTOR signaling pathways are the two most frequently altered, representing therefore interestingly targets for therapy. Moreover, somatic or germline aberrations of DNA repair genes (DRGs) have been observed at high frequency, supporting the potential role of platinum derivatives and PARP inhibitors as effective therapeutic strategies. In the future, the identification of driver mutations present at a specific stage of the disease, the classification PCa based on specific molecular alterations, and the selection of the most appropriate therapy based on biomarkers predictors of response represent the foundations for an increasingly more accurate personalized medicine.
Lingua originaleEnglish
pagine (da-a)68-73
Numero di pagine6
RivistaCancer Treatment Reviews
Stato di pubblicazionePubblicato - 2017


  • BRCA
  • Biomarkers, Tumor
  • CRPC
  • DNA Repair
  • DRG
  • Heterogeneity
  • Humans
  • Male
  • Molecular Targeted Therapy
  • Oncology
  • PARPi
  • PTEN
  • PTEN Phosphohydrolase
  • Phosphatidylinositol 3-Kinases
  • Prostate cancer
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-akt
  • Radiology, Nuclear Medicine and Imaging
  • Receptors, Androgen
  • Signal Transduction
  • TOR Serine-Threonine Kinases


Entra nei temi di ricerca di 'Prostate cancer heterogeneity: Discovering novel molecular targets for therapy'. Insieme formano una fingerprint unica.

Cita questo